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Bcl-3 is an atypical member of the IkB family that
modulates transcription in the nucleus via associa-
tion with p50 (NF-kB1) or p52 (NF-kB2) homodimers.
Despite evidence attesting to the overall physiologic
importance of Bcl-3, little is known about its cell-spe-
cific functions or mechanisms. Here we demonstrate
a T-cell-intrinsic function of Bcl-3 in autoimmunity.
Bcl-3-deficient T cells failed to induce disease in
T cell transfer-induced colitis and experimental auto-
immune encephalomyelitis. The protection against
disease correlated with a decrease in Th1 cells that
produced the cytokines IFN-g and GM-CSF and an
increase in Th17 cells. Although differentiation into
Th1 cells was not impaired in the absence of Bcl-3,
differentiated Th1 cells converted to less-pathogenic
Th17-like cells, in part via mechanisms involving
expression of the RORgt transcription factor. Thus,
Bcl-3 constrained Th1 cell plasticity and promoted
pathogenicity by blocking conversion to Th17-like
cells, revealing a unique type of regulation that
shapes adaptive immunity.
INTRODUCTION
Bcl-3 is a partner in recurrent translocations in some B cell
tumors, and high amounts of Bcl-3 are found in a number of solid
tumors (Maldonado and Melendez-Zajgla, 2011; Ohno et al.,
1990; Soma et al., 2006). Bcl-3 is a member of the IkB transcrip-
tion factor family, but unlike the classical NF-kB-inhibitory mem-
bers, Bcl-3 readily enters nuclei to modulate NF-kB activity via
association with DNA-bound p50 (NF-kB1) or p52 (NF-kB2)
homodimers. Bcl-3 may either promote or inhibit NF-kB-target
gene expression, dependent on context and by mechanisms
not well understood (Bours et al., 1993; Franzoso et al., 1992;
Fujita et al., 1993; Hinz et al., 2012; Palmer and Chen, 2008).
Nevertheless, studies with Bcl-3-deficient mice have revealed
the profound physiologic impact of this protein, particularly in im-
mune responses: Bcl-3 is essential for effective adaptive and
innate immune defenses against certain pathogens and contrib-
utes to germinal center reactions, central tolerance, and preven-
tion of autoimmune diabetes (Franzoso et al., 1997; Kreisel et al.,2011; Pe`ne et al., 2011; Ruan et al., 2010; Zhang et al., 2007).
However, the critical cell-specific functions controlled by Bcl-3
in these settings have remained elusive.
The transfer of naive CD4+ T cells into Rag1/ mice induces
colitis associated with wasting disease and is a commonly
used model of inflammatory bowel disease (IBD) (Powrie et al.,
1994a). In this transfer model, development of colitis requires
both spontaneous proliferation of T cells driven by microbiota-
derived innate signals and antigen-specific proliferation of
T cells (Feng et al., 2010). Regarding the fate of the transferred
T cells, most studies have focused on the role of the IL-12-Th1
cell and IL-23-Th17 cell axes (Powrie et al., 1994b; Yen et al.,
2006). IFN-g-deficient and T-bet-deficient T cells failed to induce
colitis (Ito and Fathman, 1997; Neurath et al., 2002) and blocking
IFN-g greatly ameliorated disease (Powrie et al., 1994b). In addi-
tion to IL-12, IL-23 has also been shown to be essential for dis-
ease development (Yen et al., 2006), but rather than specifically
drive expression of only IL-17, IL-23 may, over time, promote
conversion of Th17 cells intomore colitogenic, IFN-g-expressing
Th1-like cells (Feng et al., 2011; Morrison et al., 2013). A similar
conversion has also been observed in experimental autoimmune
encephalomyelitis (Hirota et al., 2011). IL-23 may furthermore
drive the pathogenicity of autoreactive T cells by inducing pro-
duction of GM-CSF (Codarri et al., 2011; El-Behi et al., 2011).
In the present study we identify Bcl-3 as a physiologically
relevant regulator of Th1 cell plasticity and pathogenicity.
We showed that loss of Bcl-3 in T cells blocked T cell transfer-
induced colitis as well as experimental autoimmune encephalo-
myelitis, which correlated with diminished numbers of Th1 cells
and enhanced numbers of Th17 cells. Although loss of Bcl-3
did not impair Th1 cell differentiation, it allowed for the conversion
of pathogenic GM-CSF-expressing Th1 cells into nonpathogenic
Th17-like cells.We also provide evidence that Bcl-3 stabilized the
Th1 cell phenotype in part by controlling expression of the Th17
cell transcription factor RORgt.
RESULTS
Loss of Bcl-3 in T Cells Greatly Ameliorates T Cell
Transfer-Induced Colitis
CD4+CD45RBhiCD25 naive T cells were isolated from 8- to 12-
week-old healthy wild-type (WT) and Bcl-3-deficient (Bcl3/)
mice by flow cytometry sorting and then injected into Rag1/
mice. Recipients of WT T cells steadily lost weight, beginning
as early as 4 weeks after transfer, whereas recipients of Bcl3/
T cells gained some weight during the course of the experiment;Immunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc. 555
Figure 1. Loss of Bcl-3 in T Cells Protects against T Cell Transfer-Induced Colitis and Is Associated with a Shift from Th1 to Th17 Cells
(A) CD4+CD45RBhiCD25 naive wild-type (WT) and Bcl-3-deficient (Bcl3/) T cells were injected i.p. into Rag1/mice and recipients were weighed weekly and
sacrificed 7 weeks after transfer when some mice were losing 20% of body weight (n = 6 mice/group).
(B) Colitis scores of WT or Bcl3/ T cell recipients as in (A).
(C) Total numbers of CD4+ T cells recovered form spleen (Sp), mesenteric lymph node (MLN), and colon (n = 6).
(D) Representative flow cytometric analysis of indicated cytokine expression of CD4+ T cells recovered from WT and Bcl3/ T cell recipients; summary of
percentages and absolute numbers shown on the right (n = 5 mice/group).
Results similar to those shown in (A)–(D) were obtained in a second experiment with n = 5 mice/group. Data represent means ± SD; *p < 0.05.
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Bcl-3 Controls T Cell Plasticity and Pathogenicitythey were healthy at the time recipients of WT T cells had to be
euthanized (Figure 1A). H&E staining of colon cross-sections re-
vealed severe inflammation in recipients of WT T cells, charac-
terized by profound cellular infiltration and by damaged colon
structures, whereas recipients of Bcl3/ T cells were largely
protected (Figure 1B and Figure S1A available online). Crypt ab-
scesses and submucosal inflammation were readily apparent in
colons of WT T cell recipients but essentially absent in recipients
of Bcl3/ T cells.
To examine the phenotype of transferred cells, CD4+ T cells
were recovered from spleens, mesenteric lymph nodes
(MLNs), and lamina propria of colons 7 weeks after transfer
and analyzed for cytokine production. More CD4+ T cells were
present in MLNs and especially colons (but not spleens) in
mice that had received WT compared to Bcl3/ T cells, corre-
lating with and likely in consequence of increased local inflam-
mation in the gut (Figure 1C) (see below). The percentage of
IFN-g-expressing T cells (Th1 cells) wasmuch reduced, whereas
that of IL-17-expressing T cells (Th17 cells) was much increased
if T cells lacked Bcl-3 (Figure 1D). This shift from a primarily Th1
to a Th17 cell phenotype was particularly pronounced in Bcl3/
T cells isolated from MLNs and colons, likely due to local condi-
tions favoring the generation and/or maintenance of Th17 cells.
We observed only scant T regulatory (Treg) cells and their per-
centage was similar in transferred WT and Bcl3/ T cells (Fig-
ure S1B). We also performed transfers with naive CD4+CD62L+
CD25 T cells and obtained similar results (Figures S1C–S1E).
Thus transfer of Bcl3/ T cells resulted in an unexpected skew-
ing from a predominantly Th1 to a predominantly Th17-like cell
phenotype.556 Immunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc.The Th1 to Th17 Cell Shift in Transferred Bcl3–/– T Cells
Is Cell Autonomous
To address whether Bcl-3 functioned not only cell intrinsically but
also cell autonomously (independent of trans-acting factors), we
cotransferred Thy1.1-marked WT and Thy1.2-marked Bcl3/
naive CD4+ T cells into Rag1/ mice. The relative ratio of WT
to Bcl3/ T cells recovered 4 weeks after transfer was similar
throughout spleen, mesenteric lymph node, and lamina propria
and in line with the ratio at the time of transfer, indicating that
Bcl-3 did not selectively affect localization and/or local expansion
of T cells (Figure 2A). Nevertheless, we observed far fewer IFN-g-
producing Th1 cells and many more IL-17-producing Th17 cells
among the progeny of the transferred Bcl3/ T cells compared
to their WT counterparts, especially in MLNs and colon (Fig-
ure 2B). We obtained similar results upon cotransfer of Ly5.1-
marked WT and Ly5.2-marked Bcl3/ naive CD4+ T cells
(Figure S2). These findings indicate a T-cell-autonomous role of
Bcl-3 in determining the predominant helper phenotype of trans-
ferred naive T cells. As there was no genotype-specific difference
in recovery of T cells in these cotransfers, these results also sug-
gest that the pronounced gut inflammation and associated high
levels of IFN-g seen upon transfer of only WT T cells in Figure 1
was likely responsible for the higher numbers of T cells present
in gut-associated tissues when compared to transfer of only
Bcl3/ T cells.
Bcl3–/– Th1 Cells Convert to Less-Colitogenic
Th17-Like Cells
To determine whether Bcl-3 controlled the initial differentiation of
naive T cells into either Th1 or Th17 cells, we cultured naive WT
Figure 2. Bcl-3 Functions Cell Autono-
mously to Control T Helper Cell Phenotype
Representative flow cytometric analyses of T cells
recovered from Rag1/mice 4 weeks after
cotransfer of WT Thy1.1 and Bcl3/ Thy1.2 naive
CD4+ T cells, showing (A) relative amounts of
Bcl3/ and WT T cells recovered from indicated
sites and (B) expression of indicated cytokines,
with summary of six independent cotransfers
shown below. Data represent means ± SD; *p <
0.05.
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Bcl-3 Controls T Cell Plasticity and PathogenicityandBcl3/CD4+ T cells for two rounds under standard Th1 and
Th17 cell conditions, as well as under ‘‘enhanced’’ Th17 cell con-
ditions (standard conditions plus IL-1, IL-21, and IL-23). Flow cy-
tometry analysis for signature cytokine expression under these
conditions did not reveal any differences between Bcl3/ and
Bcl-3-sufficient T cells (Figures 3A). We also differentiated cocul-
tures of Thy1.1 WT and Thy1.2 Bcl3/ naive CD4+ T cells under
Th1, Th17, or enhanced Th17 cell conditions. The ratio of WT to
Bcl3/ T cells did not change during the course of these exper-
iments, and WT and mutant T cells differentiated to similar ex-
tents (Figures S3A and S3B). Therefore Bcl-3 did not inherently
alter the potential of naive T cells to differentiate into either Th1
or Th17 cells in vitro.
This finding suggested that Bcl-3 might instead affect the
behavior of already-differentiated T cells. We differentiated WT
and Bcl3/ CD4+ T cells into Th1 cells in vitro (two rounds)
and then adoptively transferred these cells into Rag1/ mice.
Transfer of Th1-differentiated WT cells successfully induced co-
litis and weight loss, although this was not as severe and slightly
delayed when compared to transfer of naive WT cells. By
contrast, transfer of Th1-differentiated Bcl3/ T cells failed to
induce any weight loss or colon inflammation, even though these
cells produced just as much IFN-g as WT Th1 cells at time ofImmunity 41, 555–566transfer (Figures 3B, 3C, and S3C). We
recovered CD4+ T cells from recipient an-
imals 9 days, 3 weeks, and 7 weeks post-
transfer to assess production of IFN-g and
IL-17. T cells isolated from spleens and
MLNs of recipients of WT Th1 cells main-
tained this phenotype and continued to
produce IFN-g at all three times tested,
with only scant production of IL-17; by
contrast, many of the T cells isolated
from recipients of Bcl3/ Th1 cells
started to coproduce IL-17 together with
IFN-g as early as 9 days after transfer,
especially in MLNs, and by 7 weeks
most cells had progressed to produce
IL-17 exclusively (Figures 3D–3F). The
shift in production of only IFN-g, to IFN-
g+IL-17 (double producers), and finally,
to only IL-17 suggests a gradual conver-
sion from a Th1 to a Th17 cell phenotype.
Because up to almost 20% of the
in vitro differentiated Th1 cells did not
actively express IFN-g at time of transfer,it remained theoretically possible that IL-17 producers might
have been derived from a less-differentiated population,
although this still would not explain the progression through dou-
ble cytokine-producing to just IL-17-producing T cells in vivo. To
address this issue further, we optimized in vitro differentiation
conditions, such that more than 95% of the CD4+ T cells pro-
duced IFN-g (Figure 3G). At 4 weeks after transfer of these cells,
we observed as much of a shift from a Th1 to a Th17-like cell
phenotype in Bcl3/ T cells as before, but not in WT T cells,
again most evident in MLNs and colons (Figures 3H and 3I). In
a second approach, we generated Bcl3+/ (control) and Bcl3/
IFN-g-YFP reporter mice, isolated naive CD4+ T cells, and
flow cytometry sorted for YFP+ Th1 cells after in vitro differenti-
ation (above 98% purity) (Figure S3D). Upon transfer, YFP+
Bcl3/ Th1 cells again more readily converted into IL-17 pro-
ducers than their WT counterparts (Figure S3E) (Bcl3+/ control
T cells exhibited an increased tendency to convert compared
to WT, but were still significantly more stable than Bcl3/ cells).
In a third approach we also tested whether Th1 cells generated
in vivo would undergo a shift to Th17 cells after retransfer. Naive
CD4+ T cells were isolated from Bcl3+/ (control) and Bcl3/
IFN-g-YFP reporter mice and adoptively transferred into
Rag1/mice and 4 weeks later, YFP+ cells were flow cytometry, October 16, 2014 ª2014 Elsevier Inc. 557
Figure 3. Bcl3–/– Th1 Cells Convert to Nonpathogenic Th17 Cells upon Transfer
(A) Representative flow cytometric analyses of WT and Bcl3/ naive CD4+ T cells cultured under Th1, Th17 or enhanced Th17 (Th17+) cell conditions in vitro and
analyzed for expression of indicated cytokines. Summary of percentages of differentiated T cells from five independent experiments shown on the right.
(B) In vitro differentiatedWT and Bcl3/ Th1 cells were injected i.p. into Rag1/mice, and recipients were weighed weekly and sacrificed 7 weeks after transfer
(n = 6 mice/group).
(C) Colitis scores of WT or Bcl3/ Th1 cell recipients as in (B).
Results similar to those shown in (B) and (C) were obtained in a second experiment with n = 6 mice/group.
(D and E) Representative cytometric analyses for indicated cytokine expression of T cells recovered from spleen (D) andMLNs (E) at indicated times after transfer.
(F) Summary of three independent experiments as in (E) (total n = 9 mice/group).
(G) Representative flow cytometric analyses for indicated cytokine expression of highly differentiated WT and Bcl3/ Th1 cells.
(H) Representative flow cytometric analyses for indicated cytokine expression in T cells recovered from indicated sites 4 weeks after transfer of highly differ-
entiated Th1 cells into Rag1/ mice.
(I) Summary of four independent experiments as in (H).
(legend continued on next page)
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Bcl-3 Controls T Cell Plasticity and Pathogenicitysorted from spleens and then retransferred into Rag1/ mice.
Such in vivo generated YFP+ Th1 cells again exhibited more
plasticity in the absence of Bcl-3, producing notably more IL-
17, mostly as double-producers at this relatively early stage after
transfer (Figure 3J).
IL-17-producing Bcl3/ T cells isolated from MLNs 4 weeks
after transfers of in vitro differentiated Th1 cells also showed sig-
nificant coexpression of IL-22, and to a lesser degree, IL-17F,
two additional cytokines associated with the Th17 cell pheno-
type. Interestingly, these cells expressed very little GM-CSF, a
cytokine recently reported to be critical for pathogenicity of au-
toreactive T cells (Figure S3F). We also detected notably
increased RORgt protein expression and reduced amounts of
T-bet, consistent with a conversion of Th1-cell-differentiated
Bcl3/ T cells to a Th17-like cell phenotype (Figure S3G).
We investigated whetherBcl3/ Th1 cells might preferentially
convert to Treg cells. However, neither WT nor Bcl3/ Th1 cells
expressed significant amounts of Foxp3 after exposure to Treg-
cell-skewing conditions in vitro or after transfer in vivo (Figures
S3H and S3I). To rule out the possibility that CD4+ T cells isolated
from Bcl3/ mice bear a developmental defect caused by lack
of Bcl-3 in other cells, we generated mice conditionally ablated
of Bcl-3 in T cells (via Lck-Cre) (Figure S3J). Naive CD4+ T cells
from these mice also failed to induce significant pathology
upon transfer and they produced much less IFN-g and GM-
CSF and more IL-17 than control Bcl-3-heterozygous T cells
(Figures S3K and S3L) (Bcl3+/ controls exhibited a partially
increased potential to convert; see above). We further confirmed
that naive T cells isolated from mice with T-cell-specific ablation
of Bcl-3 did not differ from heterozygous controls in expression
of IL-17, IFN-g, and GM-CSF after in vitro differentiation under
either Th1 or Th17 cell conditions (Figure S3M). Finally, T cells
isolated from the conditionally ablatedmutant mice and differen-
tiated into Th1 cells in vitro also much more readily converted to
Th17-like cells upon transfer than controls and they produced
less GM-CSF (Figure S3N). Thus Bcl3/ Th1 cells converted
to less-colitogenic Th17-like cells in vivo.
Conversion of Bcl3–/– Th1 Cells Depends on Antigen and
Cytokine Stimulation
To determine whether the conversion of Bcl3/ Th1 cells into
Th17-like cells was cell autonomous, we cotransferred Ly5.1-
marked WT together with Ly5.2-marked Bcl3/ Th1-differenti-
ated cells into Rag1/mice. The ratio of these two populations
was maintained 9 days after transfer in both spleen and mesen-
teric lymph node (Figure 4A). Bcl3/ Th1 cells also preferentially
converted to produce IL-17, primarily in the gut (MLNs), and at
this early stage, IFN-g was still coproduced, while the cotrans-
ferred WT Th1 cells continued to produce IFN-g almost exclu-
sively (Figure 4B). Similar results were obtained upon cotransfer
of Thy1.1-markedWTwith Thy1.2-marked Bcl3/ Th1-differen-
tiated cells (Figures S4A and S4B).
We sought to convert previously differentiated Bcl3/ Th1
cells into Th17-like cells under in vitro standard and ‘‘enhanced’’(J) Representative flow cytometric analyses for indicated cytokine and YFP expres
sorted YFP+ Th1 cells that had been isolated from spleens of Rag1/ 4 weeks af
the IFN-g-YFP reporter. Summary of three independent experiments for IL-17 sh
Data represent means ± SD; *p < 0.05.Th17-cell-skewing conditions. Standard Th17 cell differentiation
conditions were largely ineffective in converting Bcl3/ Th1 into
Th17 cells, but enhanced conditions did allow for significant con-
version, with some cells now able to produce IL-17 alone or
together with IFN-g; by contrast, WT Th1 cells could not be con-
verted at all under any conditions (Figure 4C). We also tested
whether loss of Bcl-3 might prevent the ability of Th17-differen-
tiated cells to convert to Th1 cells under appropriate skewing
conditions in vitro, as such conversion has been well docu-
mented (Lee et al., 2009). However, both WT and Bcl3/ Th17
cells could be similarly converted to Th1-like cells (Figure S4C).
To test whether conversion of Bcl3/ Th1 to Th17 cells might
depend on (microbial) antigen recognition, we generated Bcl3/
OTIImice (ovalbumin-specific TCR), subjected naiveCD4+ T cells
isolated from these and from Bcl3/ mice to Th1 cell differenti-
ation, and cotransferred both Th1 cell populations into Rag1/
mice. T cells isolated from MLNs 3 weeks after transfer already
revealed a lower conversion in Bcl3/ OTII TCR-bearing
T cells compared to Bcl3/ T cells with a diverse TCR repertoire
(Figure 4D). Of note, more of the latter cells were recovered, likely
due to antigen-specific expansion not available to the OTII T cells
(shift in ratios; Figure 4E). To query the role of microbiota in
the fate of Bcl3/ Th1 cells, Rag1/ mice were pretreated
with antibiotics prior to transfer. This greatly reduced expression
of IL-17 and IFN-g, suggesting that microbiota were required to
maintain and/or expand and convert Th1 cells (Figure 4F). To
determine whether conversion of Bcl3/ Th1 cells depended
on IL-23 or both IL-23 and IL-12, we administered neutralizing
antibodies. Blocking IL-23 p19 eliminated conversion to IL-17
production, whereas blocking IL-12 (IL-23) p40 additionally
reduced IFN-g (Figure 4G). Thus conversion of Bcl3/ Th1 cells
into Th17-like cells was dependent on TCR stimulation and IL-23.
Bcl-3 Controls Plasticity and Pathogenicity of Th1 Cells
in Experimental Autoimmune Encephalomyelitis
To determine whether Bcl-3’s role in controlling plasticity and
pathogenicity of Th1 cells in colitis might extend to other autoim-
mune conditions, we tested an EAE model. Bcl-3 control hetero-
zygous mice and mice with T cell-specific ablation of Bcl-3
(heterozygous background) were immunized with MOG peptide
and draining lymph nodes were isolated and restimulated in vitro
with MOG under Th1 cell conditions. Analysis of T cells showed
equivalent production of IFN-g and GM-CSF (with little IL-17
expression) in Bcl3/ and control CD4+ T cells (Figure 5A).
Upon transfer into Rag1/ mice and booster immunization, re-
cipients of control MOG-primed Th1 cells developed severe
symptoms of EAE, while recipients of Bcl3/ MOG-primed
Th1 cells were fully protected from disease (Figures 5B and
S5A). In contrast to recipients of control T cells, only scant
CD4+ T cells could be recovered from spinal cords of recipients
of Bcl3/ T cells, even though we observed no difference in the
numbers of CD4+ T cells in other organs (Figure 5C). Analogous
to what we observed in the colitis model, the Bcl3/ Th1 cells
produced more IL-17 and less IFN-g, especially in MLNs, butsion of CD4+ T cells fromMLNs ofRag1/mice 4 weeks after receiving FACS-
ter initial transfer with naive Bcl3/ and control (Bcl3+/) CD4+ T cells carrying
own on the right.
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Figure 4. Bcl-3 Functions Cell Autono-
mously to Control Th1 Cell Plasticity
(A and B) Representative flow cytometric analyses
of T cells recovered from Rag1/ mice 9 days
after cotransfer of Ly5.1WT and Ly5.2 Bcl3/ Th1
cells, showing (A) relative amounts of Bcl3/ and
WT T cells recovered from indicated sites and (B)
expression of indicated cytokines in recovered
Bcl3/ and WT T cells, with summary of three
independent cotransfers shown below.
(C) Representative flow cytometric analyses of
indicated cytokine expression of in vitro generated
Th1 cells after redifferentiation under Th17 or
Th17+ cell conditions for 3 weeks, with summary of
three independent experiments on the right.
(D) Representative flow cytometric analyses of
T cells recovered from MLNs of Rag1/ mice
3 weeks after transfer of WT, OTII, Bcl3/, or
Bcl3//OTII Th1 cells for expression of indicated
cytokines, with summary of four independent ex-
periments shown below.
(E) Representative flow cytometric analyses of
relative amounts of OTII andWT,Bcl3//OTII, and
Bcl3/ T cells before and after transfer.
(F) Rag1/ mice were treated with antibiotics for
3 weeks or not treated prior to transfer of Bcl3/
Th1 cells. Shown are representative flow cyto-
metric analyses of T cells recovered from spleen
and MLN 3 weeks after transfer, with summary of
three independent experiments on the right.
(G) Rag1/ mice adoptively transferred with WT
and Bcl3/ Th1 cells were injected i.p. with indi-
cated neutralizing antibodies. Shown are represen-
tative flow cytometric analyses of T cells recovered
from MLN 3 weeks after transfer, with summary of
three independent experiments on the right.
Data represent means ± SD; *p < 0.05.
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Bcl-3 Controls T Cell Plasticity and Pathogenicityalso elsewhere, and most remarkably, they produced much less
GM-CSF, consistent with an important role of this cytokine in
EAE pathogenesis (Figure 5D).
We also induced EAE directly via immunization withMOGpep-
tide followed by a booster. Consistent with the transfer model,
mice conditionally ablated of Bcl-3 in T cells were protected
from EAE, while Bcl3+/ controls developed typical disease
symptoms (Figures S5B and S5C). Also, spinal cords of control
mice were infiltrated with T cells, while those of conditional
gene deletion were not; furthermore, compared to controls,
T cells from draining lymph nodes of conditional gene deletion560 Immunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc.mice exhibited a clear shift from Th1 to
Th17 cells and a decrease in GM-CSF
production (Figure S5D; as expected,
percentage of cytokine producers was
lower in this EAE model). Thus Bcl3/
Th1 cells converted to less-pathogenic
Th17-like cells in the context of EAE.
Bcl-3 Might Control Th1 Cell
Plasticity via an RORgt-Dependent
Mechanism
Since Bcl-3 can regulate gene expression
via associationwith p50 (NF-kB1) and p52(NF-kB2) homodimers, we asked whether in vitro differentiated
Th1 cells from NF-kB1- or NF-kB2-deficient mice might also
show increased plasticity upon transfer. NF-kB1-deficient Th1
cells were as stable as WT Th1 cells, but some NF-kB2-deficient
Th1 cells did convert into IL-17-producing cells, especially in
MLNs (Figure S6A). While this might suggest a role for p52
(NF-kB2) in mediating Bcl-3 activity, the fact that both p50
(NF-kB1) and p52 (NF-kB2) are also central to overall NF-kB ac-
tivity precludes definitive conclusions; nevertheless, these find-
ings do further implicate NF-kB in control of plasticity. We also
assessed mRNA levels of Bcl-3 in differentiated Th1 and Th17
Figure 5. Bcl-3 Controls Th1 Cell Plasticity and Pathogenicity in Experimental Autoimmune Encephalomyelitis
Control mice (Bcl3Flx/KO) and mice with T cell-specific ablation of Bcl-3 (Bcl3Flx/KO Lck-Cre+) were immunized with MOG. Ten days later, cells from draining
lymph node and spleen were isolated and restimulated in vitro under Th1 cell conditions.
(A) Representative flow cytometric analyses of restimulated T cells for indicated cytokine expression, with summary of three independent experiments on the
right.
(B) Th1 cells from (A) were transferred into Rag1/ mice and immunized with MOG. Disease score of the recipients were monitored daily (n = 6 mice/group).
(C) Total numbers of CD4+ T cells recovered from inguinal lymph node (Ing), MLN, and spinal cord (SC) at end of experiment as in (B) (n = 5 mice/group).
(D) Representative flow cytometric analyses for expression of indicated cytokines in T cells recovered from indicated sites at end of experiments (B) and (C), with
summary of data shown below (n = 5 mice/group).
Results similar to those in (B)–(D) were obtained in a separate set of experiments, n = 3 mice/group. Data represent means ± SD; *p < 0.05.
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Figure 6. Mechanisms Involved in Constraining Th1 Cell Plasticity
(A) Relative expression levels (RT-PCR) of indicated genes of in vitro generated WT and Bcl3/ Th1 cells (n = 3/group; each separately differentiated).
(B) Representative flow cytometric analyses of GFP+ T cells from MLNs for indicated cytokine expression of in vitro generated WT and Bcl3/ Th1 cells
transduced with a GFP-RORgt retrovirus or an empty retrovirus vector (EV) and transferred into Rag1/mice for 3 weeks. Summary (IL-17) of three independent
experiments shown on the right.
(C) ChIP analysis of tagged-Bcl-3 binding to Rorc promoter regions 1 through 8 in WT and tagged-Bcl-3 transgenic (Tg) Th1 cells (n = 3 mice/group).
(D) ChIP analysis of indicated NF-kB subunits binding to Rorc promoter regions 3 and 7 in WT and Bcl3/ Th1 cells (n = 3).
(E) Rorc promoter luciferase assays in Jurkat cells transfected with expression constructs for cRel, p50 and Bcl-3 as indicated (n = 3).
Two additional repeats of each experiment in (A) and (C)–(E) yielded similar results. Data represent means ± SD; *p < 0.05.
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Bcl-3 Controls T Cell Plasticity and Pathogenicitycells, but did not find a significant difference, suggesting that
Bcl-3’s activity was likely context dependent (Figure S6B).
To determine whether Bcl-3 might be involved in direct control
of IL-17 transcription, we made use of an IL-17 promoter and
enhancer-driven luciferase reporter in Jurkat cells but were un-
able to find any evidence for a role of NF-kB (Figure S6C). We
next surveyed Th1-differentiated cells for expression levels of
genes known to be relevant for the differentiation of naive
T cells into either Th1 or Th17 cells. Although both WT and
Bcl3/ in vitro-differentiated Th1 cells expressed equal levels
of IFN-g and no IL-17, the Bcl3/ Th1 cells could already be
distinguished from their WT counterparts by notably higher
amounts of the Th17 cell phenotype-associated major regulator
RORgt and lower amounts of the signal-regulator SOCS3, even
in the absence of Th17-cell-skewing conditions (Figure 6A).
Bcl3/ (as opposed to WT) Th1 cells thus appeared to be less
‘‘fixed’’ into the Th1 cell state, even after two rounds of Th1-
cell-skewing differentiation regimens, and consequently poten-
tially more likely to switch to Th17 cells with appropriate stimuli.
To determinewhether increasedRORgt expressionmight be suf-
ficient to allow Th1 cells to switch to Th17 cells, we overex-
pressed RORgt via retroviral transduction in both Bcl3/ and
WTTh1 cells, and then subjected them to Th17 cell differentiation
conditions. Overexpressed RORgt was able to break the con-
straints on plasticity even in WT Th1 cells, as we now observed
IL-17 expression in both WT and Bcl3/ Th1 cells under Th17-
cell-skewing, and especially under enhanced Th17-cell-skewing562 Immunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc.conditions, although Bcl3/ cells still expressed more IL-17
(Figure S6D). We also transferred RORgt-overexpressing Th1
cells into Rag1/ mice, and under these in vivo conditions WT
and Bcl3/ Th1 cells now produced equally high levels of
IL-17, suggesting that RORgt levels were critical for the ability
to convert to a Th17 cell phenotype in vivo (Figure 6B).
To provide further support for the notion that Bcl-3 regulates
expression of Rorc, we made use of transgenic (Tg) mice that
overexpressed Bcl-3 specifically in T cells. Naive CD4+ T from
these transgenic and from WT mice were differentiated into
Th1 and Th17 cells and assessed for Rorc expression. Overex-
pressed Bcl-3 inhibited Rorc expression in Th17 cells and further
reduced already low expression in Th1 cells (Figure S6E). To
determine whether Bcl-3 might directly regulate expression of
Rorc, we performed chromatin immunoprecipitation (ChIP) as-
says with Bcl3 Tg and WT Th1 cells, making use of the Tag on
Tg Bcl3 to allow unambiguous detection. We scanned the Rorc
regulatory region by dividing it into eight segments (Lazarevic
et al., 2011) and detected an association of Bcl-3 with segments
3 and 6/7 (Figure 6C), regions previously identified as binding
sites of c-Rel- and RelA-containing NF-kB complexes important
for induced expression of Rorc during Th17 cell differentiation
(Ruan et al., 2011). ChIP analysis of Th1-differentiated cells still
revealed the presence of c-Rel and p50 in both segments, and,
importantly, increased association of c-Rel especially in
segment 3 in the absence of Bcl-3 (Figure 6D). To confirm that
Bcl-3 may directly inhibit c-Rel-p50-mediated expression of
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luciferase reporter assay in Jurkat cells. We confirmed that
expression vectors for RelA and c-Rel could induce this reporter
(Figure S6F). Exogenously introduced c-Rel together with p50/
NF-kB1 also stimulated the Rorc-driven reporter, and this was
completely abolished in the presence of exogenously introduced
Bcl-3 (Figure 6E).
DISCUSSION
The research presented describes a physiologically critical role
for the oncoprotein Bcl-3, a modulator of NF-kB-dependent
gene transcription. We demonstrate that Bcl-3 constrains the
plasticity of Th1 cells and assures their pathogenicity in the
setting of autoimmune conditions. Bcl-3 acted cell autono-
mously to maintain a pathogenic Th1 cell phenotype and prevent
conversion to a Th17-like cell, nonpathogenic phenotype. Thus,
in contrast to naive WT T cells, their Bcl3/ counterparts failed
to induce colitis or weight loss upon transfer into Rag1/ recip-
ient mice, shifting from pathogenic, IFN-g-producing, to
nonpathogenic, IL-17-producing cells. Initial differentiation into
either Th1 or Th17 cells was not altered in the absence of Bcl-
3. However, when T cells lacking Bcl-3 were fully differentiated
into IFN-g-producing Th1 cells, either in vitro or in vivo, they
failed to maintain their phenotype upon transfer and converted
to Th17-like cells in the context of both the colitis and EAE
models. This conversion was also associated with notably
decreased production of GM-CSF, a cytokine linked to pathoge-
nicity in both models (Codarri et al., 2011; El-Behi et al., 2011;
Griseri et al., 2012). Bcl-3 functioned, at least in part, by repres-
sing expression of the Th17-cell-associated regulator RORgt in
Th1 cells. Thus Bcl3/ Th1 cells exhibited notable expression
of RORgt, making them more susceptible to conversion into
Th17 cells upon encounter with appropriate skewing signals.
Bcl-3 bound to the Rorc regulatory domain, inhibiting c-Rel-
NF-kBassociation and consequentRorc expression. These find-
ings reveal an unexpected level of regulation of T cell plasticity,
and they provide a molecular explanation for why Th1 cells do
not readily convert to Th17 cells, while the reverse conversion
from Th17 to Th1-like cells has been noted in various pathogenic
settings. Targeting Bcl-3 could therefore provide a new path to
control plasticity and pathogenicity of T cells.
Inflammatory bowel disease (IBD) is characterized by chronic
inflammation of the gastrointestinal tract and includes Crohn’s
disease and ulcerative colitis. Inappropriate activation of the
mucosal immune system in response to microbial products
plays a key role in disease progression and, in the case of
Crohn’s disease, is associated with activation of in particular
Th1 and Th17 cells, the type of IBD most similar to T cell trans-
fer-induced colitis (Bene et al., 2011). The role of the Th17 cell
signature cytokine IL-17 in Crohn’s disease remains controver-
sial though, as initial clinical trials aimed at neutralizing IL-17
worsened the disease, suggestive of an overriding protective
rather than inflammatory role for this cytokine in this disease
(Marwaha et al., 2012). Furthermore, although blocking Th1 cell
responses was quite effective in ameliorating colitis in mice (Ito
and Fathman, 1997; Neurath et al., 2002; Uhlig et al., 2006),
loss of IL-17 in transferred T cells had the opposite effect
(O’Connor et al., 2009). Curiously, IL-23, a cytokine known todrive Th17 cell responses, proved to be critical in various autoim-
mune disease settings, including IBD and EAE; however, it now
appears that this cytokine may over time drive Th17 cells to
convert into more pathogenic, IFN-g-expressing Th1-like cells
in chronic inflammatory settings (Ahern et al., 2010; Feng et al.,
2011; Hirota et al., 2011; Morrison et al., 2013). In our studies,
loss of Bcl-3 in the transferred T cells led to the preferential
loss of pathogenic IFN-g-producing cells, which converted to
IL-17-producing, nonpathogenic cells with significantly reduced
expression of GM-CSF, both in the colitis and EAEmodels. In the
latter model, Bcl3/ T cells failed to accumulate in the CNS, the
site of their antigen-driven pathogenic activity (this was also
observed when EAE was induced directly upon immunization
of naive mice, without transfer of T cells). Recent evidence sug-
gests that T cell production of GM-CSF in particular may be the
primary pathogenic driver in the EAE model, rather than IFN-g or
IL-17. Based on these findings, the Bcl-3 pathway could be a po-
tential target for therapeutic intervention in Crohn’s disease and
multiple sclerosis. Patients with Crohn’s disease were found to
exhibit elevated levels of Bcl-3 mRNA (O’Carroll et al., 2013).
On the other hand, genome-wide association studies identified
a risk variant of Bcl-3 in Crohn’s disease that appeared to be
correlated with lower expression (Fransen et al., 2010). The sig-
nificance of these observations in patients remains to be deter-
mined, especially because Bcl-3 may have divergent functions
depending on cell type and because it can be regulated by mul-
tiple mechanisms, not just levels of expression (Hinz et al., 2012;
Palmer and Chen, 2008).
The transcription factor RORgt is required for expression of
a fully differentiated Th17 cell phenotype (Ivanov et al., 2006).
This so-calledmaster regulator of Th17 cells is essentially not ex-
pressed in Th1-polarized WT T cells, but as shown here, is ex-
pressed in Bcl3/ Th1 cells, albeit at a level well below that in
Th17 cells. Upon transfer into recipients, Bcl3/ Th1 cells, but
not WT Th1 cells, converted to Th17-like cells, associated with
greatly increased expression of RORgt and reduced levels of
T-bet. The increased expression of RORgt in Bcl3/, as
opposed to WT, Th1 cells appeared to be biologically relevant,
since even WT Th1 cells transduced with RORgt became sus-
ceptible to conversion upon exposure to strong Th17-cell-polar-
izing conditions, while nontransduced cells were resistant. ChIP
analyses identified two Bcl-3-associated regions in theRorc reg-
ulatory domain, both of which contain NF-kB binding sites re-
ported to be critical for c-Rel- and RelA-induced expression of
RORgt during Th17 cell differentiation (Ruan et al., 2011).
Bcl3/ Th1 cells exhibited increased association of c-Rel with
the Rorc regulatory region, consistent with higher expression,
and addition of Bcl-3 abolished c-Rel/p50-induced expression
of an Rorc-promoter/enhancer-driven reporter in Jurkat T cells.
Bcl-3 appears to help ‘‘fix’’ the pathogenic Th1 phenotype by
suppressing expression of RORgt in these cells, but this does
not rule out other, yet unknown, targets of Bcl-3 that could
potentially be involved in this process.
T helper cells are not fully locked into their originally adapted
fate (Zhu and Paul, 2010). The potential to convert into a different
T helper type, i.e., their plasticity, is reflected in the mixed epige-
netic marks—positive and negative—present in all so-called
master regulatory gene loci, regardless of the Th cell type
analyzed and consistent with the notion that any of these majorImmunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc. 563
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if given the right signals (Kanno et al., 2012). Althoughmany such
instances of conversion have been documented,most especially
from Th17 to an apparently more pathogenic Th1-like cell in the
context of disease progression, including T cell transfer-induced
colitis and EAE, the reverse, i.e., conversion from Th1 to Th17
cells, does not appear to occur readily (although it is not totally
blocked, as shown here), but the mechanisms underlying the
apparent stability of Th1 cells have not previously been explored
(Feng et al., 2011; Lee et al., 2009; Mukasa et al., 2010; Zhu and
Paul, 2010). The present study reports that Th1 cell stability and
pathogenicity can be quite readily broken in the absence of Bcl-
3, allowing conversion into Th17-like cells associated also with
lower expression of GM-CSF, especially at anatomical sites
where Th17-cell-polarizing conditions prevail, including the
presence of IL-23 and antigens to expand T cells. Whether T
helper cells adopt a stable phenotype or exhibit plasticity and
how this relates to pathogenicity is of great interest clinically.
The identification of Bcl-3 as a positive regulator of pathogenic
Th1 cells may open new avenues to ameliorate inflammatory dis-
ease pathology.
EXPERIMENTAL PROCEDURES
Mice
Bcl3/, Nfkb2/, Bcl3 transgenic, and conditional Bcl-3/ mice have been
described previously (Franzoso et al., 1998; Franzoso et al., 1997; Tassi et al.,
2014; Zhang et al., 2013). C57BL/6, OTII, Ly5.1, and Rag1/ mice were pur-
chased from Taconic, and Thy1.1, Lck-Cre, Nfkb1/, and IFN-g-YFP reporter
mice were from Jackson. Mice were housed in NIAID facilities, and all exper-
iments were done with approval of the NIAID Animal Care and Use Committee
and in accordance with all relevant institutional guidelines.
T Cell Transfer-Induced Colitis
53 105 FACS-sorted CD4+CD45RBhiCD25 naive T cells from 8- to 12-week-
old healthy mice or 1 3 106 Th1 cells were transferred into Rag1/ mice. All
donors and recipients were males. Recipients were weighed weekly and sacri-
ficed about 7 weeks after transfer, when some of mice had lost 20% of their
original body weight. Colon inflammation scores were assessed as described
(Izcue et al., 2008).
Experimentally Induced Autoimmune Encephalomyelitis
200 mg of MOG peptide (35-55) in CFA were injected s.c. into BL/6 mice and
200 ng of pertussis toxin (PT) was delivered i.p. Auxiliary and inguinal lymph
nodes and spleens were harvested 10 days after immunization, cell suspen-
sions were cultured with 25 mg/ml MOG and 20 ng/ml IL-12 for 1 week, and
live cells were transferred into Rag1/ mice in amounts containing 1 3 106
CD4+ T cells. The recipients were boosted with 200 mg MOG/CFA/PT on the
same day. To induce EAE directly, naive mice were immunized and boosted
1 week later with MOG peptide (with CFA and PT as above).
Immunohistochemistry
Colon tissue samples were fixed with 10 ml of 10% formalin buffer and
embedded in paraffin. Sections (5 mm) were cut and stained (H&E).
Flow Cytometry
100 mm filters were used to prepare single-cell suspensions from spleen and
lymph node samples. Dead cells were removed by gradient centrifugation
with lymphocyte M (Cedarlane) and live cells stained with surface antibodies
for FACS flow cytometry analysis. To isolate lymphocytes from colon, colon
tissue cut into less than 0.1 cm pieces was digested at 37C with 3 mg/ml dis-
pase II (GIBCO), 1 mg/ml collagenase D (Roche), and 0.1 mg/ml DNase I
(Roche) for 1 hr. Digested tissue was passed through 100 mm filters, followed
by centrifugation on Percoll gradients.564 Immunity 41, 555–566, October 16, 2014 ª2014 Elsevier Inc.For intracellular staining, cells were stimulated with PMA, ionomycin, and
Golgi stop for 4 hr, stainedwith antibodies for surfacemarkers, fixed overnight,
and finally permeabilized and stained with antibodies for intracellular proteins
for 30min. Data were collected with a FACSCalibur flow cytometer (BD Biosci-
ences) and analyzed using FlowJo software (Tree Star). Antibodies to the
following markers were used: CD4 (RM4-5, eBioscience), CD3 (145-2C11,
Biolegend), TCRb (H57-597, BD Biosciences), TCR Va2 (B20.1, BD Biosci-
ences), IL-22 (Poly5164, Biolegend), IL-17F (O79-289 BDBiosciences), RORgt
(AFKJS-9, eBioscience), T-bet (eBio4B10, eBioscience), Thy1.1 (OX-7, BD
Biosciences), Thy1.2 (53-2.1, BD Biosciences), Ly5.1 (A20, BD Biosciences),
Ly5.2 (104, BD Biosciences), CD25 (PC61, BD Biosciences), Foxp3 (FJK-
16s, eBioscience), IL-17 (eBio17B7, eBioscience), and IFN-g (XMG1.2,
eBioscience).
T Cell Differentiation
Naive CD4+ T cells were isolated from 8-week-old healthy mice with the Mil-
tenyi Naive CD4+ T cell Isolation Kit II and seeded at a concentration of 13 105
cells per well in 96-well plates coated with 1 mg/ml anti-CD3 (145-2C11).
Anti-CD28 (37.51) was added to the media at 2 mg/ml and for Th1 cell differ-
entiation also 10 ng/ml IL-12 and 10 mg/ml anti-IL-4 (11B11); for Treg cells,
100 U/ml IL-2, 2 ng/ml TGF-b, 10 mg/ml anti-IL-12 (C18.2), 10 mg/ml anti-
IFN-g (XMG1.2), and 10 mg/ml anti-IL-4; for Th17 cells, 20 ng/ml IL-6,
5 ng/ml TGF-b, 10 mg/ml anti-IL-12 (C18.2), 10 mg/ml anti-IFN-g (XMG1.2),
and 10 mg/ml anti-IL-4; for Th17+ cells, in addition, IL-1 (10 ng/ml), IL-21
(50 ng/ml), and IL-23 (20 ng/ml). Mitomycin C-treated splenocytes were added
at 53 105 cells per well along with 1 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for
enhanced Th1, and for Th17 and Th17+ cell conditions. Media were changed
after 4 days and cells subjected to a second round of differentiation. For Th1 to
Th17 or Treg cell conversion experiments, Th1 cells were subjected to Th17 or
Treg cell conditions for 3 additional weeks, remaining in the same well with
media changed every 4 days. Th1 cells were transduced with a GFP-RORgt
retrovirus in the presence of 8 mg/ml polybrene, as described (Lazarevic
et al., 2011). All cytokines and antibodies noted above were purchased
from PeproTech and BioXCell, respectively, except anti-IL-12 (C18.2)
(eBioscience). In some experiments, Rag1/ mice were treated for 4 weeks
with ampicillin (1 g/l), vancomycin (500 mg/l), neomycin sulfate (1 g/l), and
metronidazole (1 g/l) in drinking water for 4 weeks prior to Th1 cell transfers.
Also, in some transfers, recipients were injected i.p. with 0.2 mg of anti-IL23
p19 (BD Biosciences) or anti-IL12/IL23 p40 (BioXCell) neutralizing anti-
bodies/mouse every 3 days.
Real-Time PCR
RNAwas isolated using the RNeasy (QIAGEN) according to themanufacturer’s
instructions. cDNA was synthesized with Superscript III (Invitrogen). Gene
expression was quantified with the TaqMan real-time PCR primers (Applied
Biosystems). The results were normalized against b-actin.
Chromatin Immunoprecipitation
Naive T cells, differentiated twice under Th1 cell conditions and stimulatedwith
plate-bound anti-CD3 for 2 hr, were analyzed for association of Bcl-3 with the
Rorc promoter region after precipitation of streptavidin binding peptide-
tagged transgenic Bcl-3 with streptavidin resin, followed by real-time PCR
with primers corresponding to Rorc promoter regions 1–8, as reported (Lazar-
evic et al., 2011). To detect association of these regions with subunits of NF-kB
in WT and Bcl-3 KO Th1 cells, ChIP grade antibodies as detailed in the exper-
iments were purchased from Santa Cruz Biotechnology.
Statistical Analysis
All data are expressed as the mean ± SD from at least three independent
experiments. Differences between groups were evaluated by unpaired Stu-
dent’s t test. p values were considered to be statistically significant when
less than 0.05.
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